Literature DB >> 3599022

A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.

H Okushima, A Narimatsu, M Kobayashi, R Furuya, K Tsuda, Y Kitada.   

Abstract

A series of [4-(substituted-amino)phenyl]pyridazinones and [4-(substituted-methyl)amino]phenyl]pyridazinones was synthesized and evaluated for inotropic activity in vitro and for cardiohemodynamic effects in vivo. Above all, 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride (4, MCI-154) and 6-[4-(4-pyridylamino)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone hydrochloride (5) showed extremely potent positive inotropic activity along with vasodilating activity. Regarding dP/dtmax (an indicator for cardiac contractility), ED30's (doses that increased dP/dtmax by 30%) of compounds 4 and 5 were 8.5 +/- 1.9 and 4.4 +/- 0.6 micrograms/kg, respectively, where that of amrinone was 471.9 +/- 94.1 micrograms/kg. Structure-activity relationships of these series are presented, and a plausible model of receptor binding is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3599022     DOI: 10.1021/jm00390a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  The calcium sensitizer drug MCI-154 binds the structural C-terminal domain of cardiac troponin C.

Authors:  Monica X Li; Shorena Gelozia; Gaddafi I Danmaliki; Yurong Wen; Philip B Liu; M Joanne Lemieux; Frederick G West; Brian D Sykes; Peter M Hwang
Journal:  Biochem Biophys Rep       Date:  2018-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.